The president who ran on his business acumen isn’t holding back in telling corporate bosses how to run their companies—or when to resign.

The Genomic Biomarkers Market represents a rapidly evolving segment within the global healthcare and biotechnology industries ...

A new market analysis projects the global myelodysplastic syndrome (MDS) treatment market will grow from an estimated value ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ pipeline to focus more on complex generics—drugs that have complex ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

The outgoing CEO’s final financial update highlighted the key issues facing his successor come their September 1 handover, ...

With autonomy from its former parent, we think Sandoz can freely allocate resources to fit its best needs and grow the business. Sandoz is one of the largest biosimilars players in the world, and we ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The omnipresence of medical misinformation has fundamentally changed how certain portions of the general public approach ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials. The Danish pharma said that the Phase II trial of coramitug (PRX004), an mAb ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...